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Objective: The objective of this study was to assess the impact of walking impairment, cardiovascular risk factors, and
comorbidity on quality of life (QOL) in patients with intermittent claudication (IC).
Material and methods: The prospective observational study was conducted in the setting of a vascular outpatient
department of a teaching hospital. QOL was assessed in 200 consecutive patients with IC, with a reduced version of the
World Health Organization Quality of Life Assessment Instrument–100. The reduced instrument assesses 17 facets of
QOL within five domains (Physical and Psychological Health, Level of Independence, Social Relationships, and
Environment). Age, gender, degree of IC, risk factors, comorbidity, as recommended by the Society for Vascular
Surgery/North American Chapter of the International Society for Cardiovascular Surgery (SVS/ISCVS), and the
presence of back, hip, or knee symptoms were analyzed as possible predictors of QOL. Multiple regression analyses were
run with each of the QOL facets and domains as dependent variable. A probability value of less than .05 was considered
to be statistically significant.
Results: Male gender was found to be a predictor of better scores for Energy and Fatigue and for Sleep and Rest. Women
had more Negative Feelings. The presence of back, hip, or knee symptoms was a significant predictive value for many
aspects of QOL. With more concomitant diseases, patients had lower scores on the facets of Overall QOL and General
Health and of Energy and Fatigue and showed more dependence on medication and treatments. The degree of IC, as
expressed in the SVS/ISCVS classification, was a statistically significant predictor of QOL on the domain Level of
Independence and its facets Mobility, Activities of Daily Living, and Working Capacity and the facets Pain and
Discomfort, Sexual Activity, and Transport. Hypertension was the second most important single predictor of QOL in
patients with IC.
Conclusion: QOL in patients with IC is only partially determined by the severity of walking limitation as expressed in the
SVS/ISCVS classification. The significant impact of cardiovascular risk factors and comorbidity and the presence of back,
hip, or knee symptoms on QOL should be recognized and taken into account in the treatment policy. (J Vasc Surg 2002;
36:94-9.)
Intermittent claudication (IC) is a frequently occurring
expression of peripheral arterial occlusive disease (PAOD),
usually with a benign course for the legs.1 Although the
presenting symptom may seem innocent, concomitant cor-
onary disease and cerebrovascular disease are serious threats
to the patient’s life.2 Treatment results in patients with IC
are traditionally expressed as changes in ankle blood pres-
sures and walking distance.3 Because arteriosclerosis is a
chronic progressive and incurable disease, for a long time,
relief of symptoms was the main goal of treatment. How-
ever, during the last years, quality of life (QOL) has become
an accepted measure of disease impact and therapeutic
outcome in patients with vascular disease.4-7 Accordingly,
the goal of treatment of patients with IC has shifted from
mere palliation of symptoms to the preservation or im-
provement of QOL. The impact of IC on QOL has been
highlighted in several studies.8-10 However, in these stud-
ies, the role of cardiovascular risk factors and the impact of
concomitant disease on the QOL of these patients are
generally not included as variables. Therefore, the aim of
this study was to assess the relative impact of age, gender,
degree of claudication, cardiovascular risk factors, comor-
bidity, and the presence of back, hip, or knee symptoms on
QOL in patients with IC.
MATERIAL AND METHODS
Between January 1999 and June 2000, QOL was as-
sessed in patients with IC who agreed to participate in the
study at the vascular unit of the St Elisabeth Hospital in
Tilburg, The Netherlands. Two hundred patients were
included in the study: 135 men and 65 women, with a
mean age of 63 years (range, 42 to 83 years). Diagnosis was
suspected on history and physical examination in 215 pa-
tients and could be confirmed with treadmill performance
and ankle blood pressure in 207 patients. Seven of the
patients refused or were not capable of participation.
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Apart from patients with dementia and those who were
blind or deaf, no patients were excluded from the study. In
all patients, degree of walking impairment, risk factors
(smoking and hyperlipidemia), and comorbidity (hyperten-
sion, cardiac, carotid, renal and pulmonary status, diabetes
mellitus) were recorded according to the Society for Vas-
cular Surgery/North American Chapter of the Interna-
tional Society for Cardiovascular Surgery (SVS/ISCVS;3
Tables I and II). Because of the impact on mobility, the
presence of back, hip, or knee symptoms unrelated to
vascular disease also were recorded. QOL was assessed with
a reduced version of the World Health Organization Qual-
ity of Life Assessment Instrument–100 (WHOQOL-
100).11 The WHOQOL-100 is a generic, multidimen-
sional, self-report QOL measure that is easy to score and
has good psychometric properties.12 The WHOQOL-100
has been used in a wide variety of patient popula-
tions.10,13,14 The instrument has been developed simulta-
neously and cross-culturally in 15 centers around the
world.15 It consists of 100 questions for assessment of 24
facets of QOL within six domains (Physical Health, Psy-
chological Health, Level of Independence, Social Relation-
ships, Environment, and Spirituality/Religion/Personal
Beliefs) and a generic evaluative facet, Overall QOL and
General Health. Each facet is represented by four ques-
tions. The response scales are 5-point scales. Scores on each







No. of patients 37 81 82
Gender (male/female) 31/6 53/28 51/31
Mean age (years) 60.6 63.7 62.8
ABI 0.70 (0.52-0.95) 0.68 (0.33-0.93) 0.53 (0.24-0.88)
Mild claudication: Completion of standard treadmill exercise (5 minutes at 2 mph on 12% incline); ankle pressure after exercise 50 mm Hg, but at least 20
mm Hg lower than resting value. Moderate claudication: Between mild and severe. Severe claudication: Completion of standard treadmill exercise not possible;
ankle pressure after exercise  50 mm Hg.
ABI, Ankle brachial index.
Table II. Distribution of risk factors and comorbidity, specified according to SVS/ISCVS, in 200 patients with IC who
underwent study for QOL
None (0) Mild (1) Moderate (2) Severe (3)
Diabetes mellitus 168 (84%) 11 (6%) 15 (8%) 6 (3%)
Tobacco use 25 (13%) 43 (22%) 73 (37%) 59 (30%)
Hypertension 106 (53%) 50 (25%) 34 (17%) 10 (5%)
Hyperlipidemia 94 (47%) 38 (19%) 27 (14%) 41 (20%)
Cardiac status 136 (68%) 37 (19%) 25 (13%) 2 (1%)
Carotid status 172 (86%) 7 (4%) 15 (8%) 6 (3%)
Renal status 192 (96%) 3 (2%) 3 (2%) 2 (1%)
Pulmonary status 179 (90%) 12 (6%) 8 (4%) 1 (1%)
SVS/ISCVS grading system for cardiovascular risk factors and comorbidity3:
Diabetes mellitus: 0, none; 1, adult onset, controlled with diet or oral agents; 2, adult onset, insulin controlled; 3, juvenile onset.
Tobacco use: 0, none or none for last 10 years; 1, none current, but smoked in last 10 years; 2, current (includes abstinence less than 1 year), less than 1 pack/day;
3, current, greater than 1 pack/day.
Hypertension: 0, diastolic usually lower than 90 mm Hg; 1, controlled with single drug; 2, controlled with two drugs; 3, requires more than two drugs or is
uncontrolled.
Hyperlipidemia: 0, cholesterol (low density lipoprotein and total) and triglyceride levels within normal limits for age; 1, readily controllable with diet; 2,
requiring strict dietary control; 3, same as mild, but severe enough to require dietary and drug control.
Cardiac status: 0, asymptomatic with normal electrocardiogram; 1, asymptomatic but with either remote myocardiac infarction with history (6 months),
occult myocardial infarction with electrocardiogram, or fixed defect on dipyridamole thallium or similar scan; 2, any one of stable angina, no angina but
significant reversible perfusion defect on dipyridamole thallium scan, significant silent ischemia (1% of time) on Holter monitoring, ejection fraction 25% to
45%, controlled ectopy or asymptomatic arrhythmia, history of congestive heart failure that is now well compensated; 3, any one of unstable angina,
symptomatic or poorly controlled ectopy/arrhythmia (chronic/recurrent), poorly compensated or recurrent congestive heart failure, ejection fraction less than
25%, myocardial infarction within 6 months.
Carotid disease: 0, no symptoms, no evidence of disease; 1, asymptomatic but with evidence of disease determined with duplex scan or other accepted
noninvasive test or arteriogram; 2, transient or temporary stroke; 3, completed stroke with permanent neurologic deficit or acute stroke.
Renal status: (refers to stable levels, not transient drops or elevations in response to intravenous medication, hydration, or contrast media) 0, no known renal
disease, normal serum creatinine level; 1, moderately elevated creatinine level, as high as 2.4 mg/dL; 2, creatinine level, 2.5 to 5.9 mg/dL; 3, creatinine level
greater than 6.0 mg/dL, or on dialysis or with kidney transplant.
Pulmonary status: 0, asymptomatic, normal chest radiograph film, pulmonary function tests within 20% of predicted; 1, asymptomatic or mild dyspnea on
exertion, mild chronic parenchymal radiograph changes, pulmonary function tests 65% to 80% of predicted; 2, between 1 and 3; 3, vital capacity less than 1.85
L, forced expiratory volume in 1 second less than 1.2 L or less than 35% of predicted, maximal voluntary ventilation less than 50% of predicted, partial pressure
of carbon dioxide greater than 45 mm Hg, supplemental oxygen use medically necessary, or pulmonary hypertension.
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facet and domain can range from 4 to 20. A higher score
indicates that respondents evaluate their functioning on the
respective domains and facets of QOL as being better,
except for the facets Pain and Discomfort, Negative Feel-
ings, and Dependence on Medication/Treatments, which
have an inverse score. To adapt the instrument for patients
with IC and to limit patient burden of completion of 100
questions, the original WHOQOL-100 was reduced to the
facets and domains that were relevant to this patient group.
After a pilot study in 40 patients, with criteria for the
distribution of answers (kurtosis, which describes the
peakedness of the distribution, and skewness, which means
that the length of one of the tails of the distribution, relative
to the central section, is disproportionate to the other) and
internal consistency (Cronbach’s , a measure for the reli-
ability of the instrument), the instrument could be reduced
to 17 facets (68 questions). Because the original instrument
was reduced with the elimination of only entire facets,
which are independent components, the validity and reli-
ability of the WHOQOL-100 were preserved.
Statistics. Age, gender, risk factors, comorbidity, and
SVS/ISCVS classification of IC were tested as possible
predictors of QOL. Multiple regression analyses (MRAs)
were run with each of the QOL facets and domains as
dependent variables. Each MRA (stepwise method) con-
sisted of four blocks of variables.
The demographic variables, gender and age, were en-
tered in block 1. The second block consisted of the pres-
ence of back and hip/knee symptoms. Block 3 contained
the risk factors smoking and hyperlipidemia. Two series of
MRAs were run, with the fourth block containing the
number of concomitant diseases in the first series and the
nature of the concomitant disease (hypertension, cardiac,
carotid, renal and pulmonary status, diabetes mellitus) and
the SVS/ISCVS classification of IC in the second series.
Before performing the MRAs, we examined the distribu-
tions of the variables involved. In the case of carotid, renal,
and pulmonary status, exploration revealed extreme skew-
ness and kurtosis scores that could not be improved satis-
factory with logarithmic transformations. Furthermore, ad-
ditional data exploration pointed at violations of the
linearity assumption. With these results of evaluation taken
together, a decision was made to dichotomize the measures
of these variables to absent or present. The degree of IC and
the severity of the other risk factors and comorbidity are
expressed as none, mild, moderate, or severe, so that the
predictive value of these independent variables on QOL
would correlate with the change and direction (increase or
decrease) of the severity.
Differences in age, distribution of risk factors, and
comorbidity between the three categories of claudication
were tested with the Kruskal-Wallis test. A possible differ-
ence in gender between the three categories of IC was
examined with a 2 test. For all calculations a probability
value of less than .05 was considered to be statistically
significant.
RESULTS
No statistically significant differences were found in age
and gender or in the distribution of risk factors and comor-
bidity between the three categories of IC. Back and hip or
knee symptoms were present in 13% and 10% of the pa-
tients, respectively.
Male gender was a major predictor for higher scores on
the domain Physical Health and its components of Energy
and Fatigue and of Sleep and Rest. Female gender associ-
ated exclusively with more Negative Feelings.
From the first series of MRAs, patients with more
concomitant diseases appeared to have lower scores on
Overall QOL and General Health, Energy and Fatigue, and
Dependence on Medication/Treatments. When patients
had back, hip, or knee symptoms, their QOL scores were
lower on all facets except for Sleep and Rest, Negative
Feelings, Dependence on Medication/Treatments, Home
Environment, and Opportunities for Acquiring New Infor-
mation/Skills.
The second series of MRAs (Table III) showed that
increasing IC, as expressed in the SVS/ISCVS classifica-
tion, predicted a lower QOL on the domain Level of
Independence and its facets Activities of Daily Living and
Working Capacity. Moreover, the severity of IC was the
only variable with a substantial predictive value for the facet
Mobility (domain Level of Independence). In addition,
more severe IC was associated with more Pain and Discom-
fort, lower scores on the facet Sexual Activity, and more
problems with Transport. Hypertension emerged as an
important factor for QOL with a significant predictive value
for various aspects such as Overall QOL and General
Health, Energy and Fatigue, the domain Level of Indepen-
dence and its facets Dependence on Medication/Treat-
ments and Working Capacity, and the facets Recreation/
Leisure and Transport.
Specifically, nonsmokers, patients with mild smoking
behavior, and patients with a compromised carotid or pul-
monary status indicated that they felt more dependent on
medication and treatments. Patients with pulmonary re-
strictions had higher scores for the facet Sleep and Rest, and
patients with hyperlipidemia scored lower for Self-esteem.
Age and diabetes mellitus had no significant predictive
value for any QOL aspects in patients with IC. Finally, no
significant predictors of QOL were seen on the domain
Social Relationships and the facets Personal Relationships
and Home Environment.
DISCUSSION
QOL scores in patients with IC are the result of influ-
ences of PAOD and of comorbidity. Because walking im-
pairment is only one component of the clinical entity, other
aspects should be evaluated as well to understand the
impact of IC on patient’s QOL. These results show that the
predictive value of walking impairment, as expressed in the
SVS/ISCVS classification, for the patients’ QOL is limited
to the physical aspects of QOL: Pain and Discomfort,
Mobility, Activities of Daily Living, Working Capacity,
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Sexual Activity, and Transport. This is in concordance with
earlier reports,10,16 which describe the limited effect of
increasing IC on QOL as a whole.
The importance of risk factors and comorbidity for the
development of PAOD and for the prognosis of patients
with it has been documented extensively.2,17,18 For in-
stance, IC has been shown to be a substantial predictor of
cardiovascular morbidity and mortality, independent of
associated coronary ischemia and other cardiovascular risk
factors, in ambulatory elderly patients.19 Although patients
Table III. Results from stepwise multiple regression analysis with age, gender, nonvascular back, hip, and knee
symptoms, risk factors, comorbidity (SVS/ISCVS classification), and degree of IC (SVS/ISCVS classification) as
independent variables (predictors of QOL) and WHOQOL facets and domains as dependent variables
Dependent variable Predictor of QOL  value R2 change R2 total
Overall QOL and general health (P  .001) Hypertension .248 0.061 0.061
Physical health (P  .000) Male gender .306 0.089 0.089
Back pain .206 0.037 0.126
Renal status .174 0.030 0.156
Pain and discomfort (P  .000) Back pain .312 0.087 0.087
IC classification .151 0.023 0.110
Energy and fatigue (P  .007) Male gender .173 0.034 0.034
Hypertension .155 0.024 0.058
Sleep and rest (P  .000) Male gender .308 0.091 0.091
Pulmonary status .156 0.024 0.115
Psychological health
Positive feelings (P  .007) Renal status .207 0.043 0.043
Thinking, learning, memory, concentration –   
Self-esteem (P  .008) Hyperlipidemia .205 0.042 0.042
Body image and appearance –   
Negative feelings (P  .000) Female gender .297 0.088 0.088
Level of independence (P  .000) Hypertension .218 0.053 0.053
IC classification .208 0.043 0.096
Mobility (P  .000) IC classification .290 0.084 0.084
Activities of daily living (P  .008) IC classification .204 0.042 0.042
Dependence on medication/treatments
(P  .000)
Smoking .161 0.036 0.036
Hypertension .254 0.073 0.109
Pulmonary status .170 0.032 0.141
Carotid status .165 0.026 0.167
Working capacity (P  .000) Back pain .255 0.040 0.040
Hypertension .226 0.054 0.094
IC classification .166 0.027 0.121
Social relationships No significant predictors of QOL
Personal relationships No significant predictors of QOL
Social support
Sexual activity (P  .006) Carotid status .216 0.033 0.033
IC classification .195 0.037 0.070
Environment
Physical safety and security –   
Home environment No significant predictors of QOL
Financial resources –   
Health and social care –   
Opportunities for acquiring new
information/skills (P  .023)
Cardiac status .175 0.031 0.031
Recreation/leisure (P  .009) Hypertension .201 0.041 0.041
Physical environment –   
Transport (P  .003) IC classification .192 0.041 0.041
Hypertension .162 0.026 0.067
Spirituality, religion, personal beliefs – – – –
Scores on pain and discomfort, negative feelings, and dependence on medication/treatments are inverse. Higher scores indicate lower QOL.
IC classification: Mild, moderate, or severe IC according to SVS/ISCVS.3
 value: Indicates whether relation between predictor and facet of QOL is positive or negative. In Table, negative  value indicates that low scores on
independent variables (mild claudication, absence of back, hip, or knee symptoms, absence of carotid, renal, and pulmonary comorbidity, less severe diabetes
mellitus, tobacco use, hypertension, hyperlipidemia, and cardiac comorbidity) predict higher score on dependent variables (ie, respective domains or facets of
QOL). Negative  value for gender indicates male gender to be predictor of QOL, and positive  value means that female gender is predictor of QOL facet
or domain.
R2 change: indicates proportion of variance of dependent variable (ie, facet or domain of QOL) that is explained by independent variable in that row.
R2 total: reflects total proportion of variance of dependent variable that is explained by independent variables that are included in model up to that point.
Significance: of used model is expressed with P value. P value  .05 was considered statistically significant.
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seek help for a walking problem, the systemic risk of PAOD
is the real threat to their lives. Facing this reduces IC to a
relatively innocent ailment marking a more serious under-
lying disease.
These data indicate that, in addition to walking impair-
ment, concomitant disease plays an important role for most
aspects of QOL in patients with IC. This does not detract
from the value of improved walking for a better functional
status, which will be appreciated by the patient, even in the
presence of important comorbidity. However, the gains
with respect to QOL may be small because the predictive
value of walking impairment is limited to physical aspects.
Concerning the finding that increasing IC only affects
QOL with regard to the facet Mobility,10 patients with IC
and important comorbidity may gain some improvement in
functional status but are unlikely to enjoy important QOL
benefits from improving walking distance only. Optimizing
their medical condition may be of greater importance for
QOL.
Patients with pulmonary restrictions have better scores
for Sleep and Rest. Because QOL assesses the personal
evaluation of functioning, this subgroup of patients, with
predominantly mild to moderate pulmonary impairments
(Table II), appreciates sleep to compensate for the efforts of
dyspnea.
Heavy smokers indicate less dependence on medication
and treatments. Although this may seem contradictory, one
might speculate that the perception of dependency of a
person who is used to dependence on tobacco has been
modulated. In other words, dependency as observed may
not be experienced as such.
The importance of back and hip or knee symptoms for
QOL in patients with IC is in concordance with Feinglass et
al,20 who reported on its negative predictive value for
physical functioning. Nonvascular back, hip, or knee symp-
toms are relatively frequent in patients with IC and appear
to be significant predictors for many aspects of QOL. If
present in claudicants, these symptoms should not be ig-
nored but treated. Relief of these symptoms promises a
more profound influence on QOL than attempts to im-
prove the peripheral vascular status.
No significant predictive value was seen for age. Except
for the study by Barletta et al,16 who found a relation
between age and health status in patients with IC, this
finding is concordant with most other studies. More sur-
prising were the findings that diabetes mellitus did not have
a predictive value for QOL and that hypertension appeared
to be a major predictor. This may be explained by the fact
that many of the risk factors and comorbidities that ap-
peared to be of importance for the QOL in patients with IC
are present in patients with diabetes as well. QOL in
patients with IC and diabetes may be determined largely by
the same factors. Moreover, the milder forms of diabetes
can be treated with diet and lifestyle modification, with the
purpose to keep glucose level within limits. This relatively
small interference with daily life and the knowledge that
severe complications of diabetes are not evident for 15 to
20 years after its onset may account for diabetes being not
a predictor of QOL in patients with IC. Although the
severity of diabetes according to the SVS/ISCVS reporting
standards3 depends on the age of onset of the disease and
the method of treatment, the severity of hypertension is
rated according to the number of drugs needed for control.
The number of antihypertension drugs needed every day
directly confronts the patient with the severity of this
condition, generally known to be associated with important
implications for the vascular and cardiac status. The
method of rating the severity of diabetes and hypertension
may be responsible for the counterintuitive findings con-
cerning the predictive value of these two variables for QOL
in patients with IC.
Although convincing evidence exists that conservative
treatment should be the first choice for patients with
IC,21,22 the increasing possibilities of minimally invasive
percutaneous procedures have contributed to more active
methods of treatment. Studies that focus on patients with
IC have shown that percutaneous transluminal angioplasty
(PTA) may produce favorable results with respect to pa-
tency, ankle-brachial indices, walking distance, and even
health-related QOL in the short term.23-25 However, mid-
term and long-term results failed to show benefits from
PTA over exercise training and sanitation of risk factors. A
deterioration in QOL 12 months after a successful PTA has
been attributed to the impact of increasing comorbid-
ity.26,27 These data show that risk factors and comorbidity
also have an important impact on QOL in patients with IC
at baseline, before treatment. Thus, successful treatment in
terms of improving walking distance only will have a limited
effect on patient QOL.
The clinical importance of the statistically significant
predictors of QOL in this study may be questioned because
of the modest strength of the association between depen-
dent and independent variables. In the absence of an alter-
native method for assessment of the importance of these
variables and facing the fact that patients with IC are known
to have important comorbidity, the results of this study may
help to direct treatment options in a way to satisfy patient
needs.
In the Transatlantic Inter-Society Consensus docu-
ment (TASC),6 the statement is found that although the
limitation in walking may be the only symptom of PAOD,
the overriding issue in the management of patients with IC
is their risk of development of severe and often fatal cardio-
vascular complications. In addition, this study indicates
that the appraisal of risk factors and comorbidity in patients
with IC is essential for the interpretation of QOL assess-
ments. A challenge for those caring for patients with IC is
to explain to them the importance of treating comorbidity
and risk factors instead of only proposing attractive meth-
ods of palliation for their walking problem.
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